You have a sampling bias. As the article notes, the Endocrine Society generally recommends replacement doses of 75-100 mg weekly for injections. The TRAVERSE trial, which was the definitive trial establishing cardiovascular safety for medically appropriate TRT, used gels rather than injection, but repeat-tested and adjusted the dose to maintain T between 350 and 750 ng/dL, which the great majority of men will achieve at these doses. Peter Attia uses 50 mg twice weekly for most of his TRT patients, and has never gone above 200 mg/week; Kevin White, who guided Matt Kaeberlein onto injected TRT, similarly uses 50 mg twice weekly in nearly all cases.
Read the actual passage. The guidelines do not say that you need to discontinue TRT once the hematocrit reaches the magic number of 54%: they say you should begin close monitoring and make adjustments when it reaches 50-52%, and that therapy should be reduced, paused, OR discontinued if it continues to climb above 54%.

Thorin:
I asked Google “Is heart failure one of the elements of MACE in cardiology”. Here is part of the answer I got.
Yes, heart failure is often included as one of the elements of Major Adverse Cardiovascular Events (MACE) in cardiology. The exact components of MACE can vary between different clinical studies, but heart failure is a common and serious outcome frequently monitored.
Read original sources. Google makes free use of unreliable sources that get a lot of clicks, hallucinates, and tells you what it thinks you want to hear.
There are studies that use heart failure as part of MACE, but they’re rare: usually, MACE means MI, stroke, or cardiovascular death, and sometimes extends to revascularization and/or unstable angina.
In this case, we don’t have to guess: just follow the link that LukeMV provided to the study in question and then retrieve the free full text.
“MACE were defined as a composite of death from any cause, MI (I21–I23) and stroke (I63, G45). VTE included deep vein thrombosis (I82 and Z86.718) and pulmonary embolism (I26).”
Including all-cause mortality under MACE is a highly unorthodox maneuver, but (a) it’s not heart failure, and (b) that implies that the risk of overdoing it on TRT might be higher than the abstract implies. “However, MACE/VTE subset analysis revealed an increased risk of developing acute MI (OR 1.81, 95% CI 1.2–2.7) and VTE (OR 1.51, 95% CI 1.17–1.94) in the men with polycythemia. However, the risk of death (OR 1.14, 95% CI 0.78–1.65) or developing a stroke (OR 0.91, 95% CI 0.64–1.29) was similar.” That’s a bit reassuring on death, though it’s not clear they are powered to rule it out.